Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

QUILT 2.023: A Study of N-803 in Combination With Current Standard of Care vs Standard of Care as First-Line Treatment for Patients With Stage 3 or 4 NSCLC.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03520686
Recruitment Status : Recruiting
First Posted : May 11, 2018
Last Update Posted : March 3, 2021
Sponsor:
Information provided by (Responsible Party):
ImmunityBio, Inc.

Brief Summary:
This is a phase 3, open-label, 3-cohort, randomized study to compare the safety and efficacy of N-803 in combination with the current standard of care (experimental arms) versus standard of care alone (control arms), as first-line treatment for subjects with stage 3 or 4 advanced or metastatic NSCLC. Treatment will continue for up to 2 years, or until the patient experiences confirmed progressive disease or unacceptable toxicity, withdraws consent, or if the investigator feels that it is no longer in the patient's best interest to continue treatment. Patients will be followed for disease progression, post-therapies, and survival through 24 months after the first dose of study drug.

Condition or disease Intervention/treatment Phase
Non Small Cell Lung Cancer Drug: N-803 + Pembrolizumab Drug: N-803 + Carboplatin + Nab-paclitaxel + Pembrolizumab Drug: N-803 + Cisplatin or Carboplatin + Pembrolizumab + Pemetrexed Drug: Pembrolizumab Drug: Carboplatin + Nab-paclitaxel or Paclitaxel + Pembrolizumab Drug: Cisplatin or Carboplatin + Pembrolizumab + Pemetrexed Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 1538 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: QUILT 2.023: A Phase 3, Open-Label, 3-Cohort Randomized Study of N-803, in Combination With Current Standard of Care VS Standard of Care as First-Line Treatment for Patients With Advanced or Metastatic NSCLC.
Actual Study Start Date : May 18, 2018
Estimated Primary Completion Date : July 1, 2023
Estimated Study Completion Date : July 1, 2024

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Cohort A (Experimental) Drug: N-803 + Pembrolizumab

The treatment plan in the experimental arm will consist of repeated 3-week cycles for a maximum treatment period of 2 years, in accordance with the following dosing regimen:

Day 1, every 3 weeks:

  • Pembrolizumab (200 mg intravenous infusion [IV])
  • N-803 (15 μg/kg subcutaneously [SC])

Experimental: Cohort B (Experimental) Drug: N-803 + Carboplatin + Nab-paclitaxel + Pembrolizumab

The treatment plan in the experimental arm of Cohort B will consist of an induction period of repeated 3-week cycles for 4 cycles then a maintenance period of repeated 3-week cycles for a maximum treatment period of 2 years, in accordance with the following dosing regimen:

Induction (4 cycles):

Day 1, every 3 weeks:

  • Carboplatin (up to 900mg IV)
  • Nab-paclitaxel (100mg/m² IV)
  • Pembrolizumab (200mg IV)
  • N-803 (15 μg/kg SC)

Day 8:

  • Nab-paclitaxel (100mg/m² IV)

Day 15:

  • Nab-paclitaxel (100mg/m² IV)

Maintenance:

Day 1, every 3 weeks:

  • Pembrolizumab (200mg IV)
  • N-803 (15 μg/kg SC)

Experimental: Cohort C (Experimental) Drug: N-803 + Cisplatin or Carboplatin + Pembrolizumab + Pemetrexed

The treatment plan in the experimental arm of Cohort C will consist of an induction period with repeated 3-week cycles for 4 cycles, then a maintenance period of repeated 3-week cycles for a maximum treatment period of 2 years, in accordance with the following dosing regimen:

Induction (4 cycles):

Day 1, every 3 weeks:

  • Cisplatin (75mg/m²) or Carboplatin (up to 900mg IV)
  • Pembrolizumab (200mg IV)
  • Pemetrexed (500mg/m² IV)
  • N-803 (15 μg/kg SC)

Maintenance:

Day 1, every 3 weeks:

  • Pembrolizumab (200mg IV)
  • N-803 (15 μg/kg SC)

Active Comparator: Cohort A (Control) Drug: Pembrolizumab

Drug: Pembrolizumab

The reference treatment will consist of repeated 3-week cycles for a maximum treatment period of 2 years, in accordance with the following dosing regimen:

Day 1, every 3 weeks:

• Pembrolizumab (200 mg IV)


Active Comparator: Cohort B (Control) Drug: Carboplatin + Nab-paclitaxel or Paclitaxel + Pembrolizumab

The treatment plan in the control arm of Cohort B will consist of an induction period of repeated 3-week cycles for 4 cycles then a maintenance period of repeated 3-week cycles for a maximum treatment period of 2 years, in accordance with the following dosing regimen:

Induction (4 cycles):

Day 1, every 3 weeks:

  • Carboplatin (up to 900mg IV)
  • Nab-paclitaxel (100mg/m² IV) or Paclitaxel (200mg/m² IV)
  • Pembrolizumab (200mg IV)

Day 8:

  • Nab-paclitaxel (100mg/m² IV) -if assigned to receive

Day 15:

  • Nab-paclitaxel (100mg/m² IV) -if assigned to receive

Maintenance:

Day 1, every 3 weeks:

  • Pembrolizumab (200mg IV)

Active Comparator: Cohort C (Control) Drug: Cisplatin or Carboplatin + Pembrolizumab + Pemetrexed

The treatment plan in the control arm of Cohort C will consist of an induction period with repeated 3-week cycles for 4 cycles, then a maintenance period of repeated 3-week cycles for a maximum treatment period of 2 years, in accordance with the following dosing regimen:

Induction (4 cycles):

Day 1, every 3 weeks:

  • Cisplatin (75mg/m²) or Carboplatin (up to 900mg IV)
  • Pembrolizumab (200mg IV)
  • Pemetrexed (500mg/m² IV)

Maintenance:

Day 1, every 3 weeks:

  • Pembrolizumab (200mg IV)




Primary Outcome Measures :
  1. Progression Free Survival (PFS) [ Time Frame: 24 Months ]
    Defined by RECIST Version 1.1 based on BICR


Secondary Outcome Measures :
  1. Overall Survival (OS) [ Time Frame: 24 Months ]
  2. Overall Response Rate (ORR) [ Time Frame: 24 Months ]
    Defined by RECIST Version 1.1 based on BICR

  3. Duration of Response (DOR) [ Time Frame: 24 Months ]
    Defined by RECIST Version 1.1 based on BICR.

  4. PFS [ Time Frame: 24 Months ]
    Defined by iRECIST based on BICR.

  5. Overall Response Rate (ORR) [ Time Frame: 24 Months ]
    Defined by iRECIST based on BICR.

  6. Duration of Response (DOR) [ Time Frame: 24 Months ]
    Defined by iRECIST based on BICR.

  7. Disease Control Rate (DCR) [ Time Frame: 2 Months ]
    Confirmed CR, PR, or SD lasting for at least 2 months by RECIST Version 1.1 based on BICR

  8. Quality of Life based on Patient Reported Outcomes Questionnaires [ Time Frame: 24 Months ]
    FACT-L


Other Outcome Measures:
  1. Incidence of treatment-emergent AEs and SAEs [ Time Frame: 24 Months ]
    Graded using the NCI CTCAE Version 5.0

  2. Immunogenicity profile of N-803 in combination with pembrolizumab. [ Time Frame: 24 Months ]
    Detection of anti-drug antibodies

  3. Tumor molecular profiles and correlations with subject outcomes [ Time Frame: 9 Weeks ]
    Genomic sequencing of tumor cells from tissue



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Age ≥ 18 years old.
  2. Able to understand and provide a signed informed consent that fulfills the relevant IRB or Independent Ethics Committee (IEC) guidelines.
  3. Histologically-confirmed stage 3 or 4 NSCLC disease. Subjects with stage 3 disease must not be candidates for treatment with surgical resection or chemoradiation.
  4. Subjects must not have received prior systemic chemotherapy for advanced or metastatic NSCLC. Previous neoadjuvant/adjuvant chemotherapy is allowed if completed ≥ 6 months before diagnosis of metastatic disease. Subject's with newly-diagnosed stage 4 NSCLC may have previously received systemic chemotherapy for stage 3 NSCLC.
  5. For Cohort A only: NSCLC tumors must have PD-L1 expression (i.e. a TPS ≥1%) as determined by an FDA-approved test.
  6. The subject's tumor must not harbor an EGFR sensitizing (activating) mutation or ALK translocation or targetable genomic aberration in BRAF, ROS1 or NTRK. EGFR sensitizing mutations are those mutations that are amenable to treatment with tyrosine kinase inhibitors including erlotinib, gefitinib, or afatinib. Investigators must be able to produce the source documentation of the EGFR mutation, ALK translocation, and BRAF, ROS1, and NTRK status. If any of the genomic changes described above are detected, additional information regarding the mutation status of other molecules is not required. If unable to test for these molecular changes, formalin fixed paraffin embedded tumor tissue of any age should be submitted to a central laboratory designated by the Sponsor for such testing. Subjects will not be randomized until the EGFR , BRAFT, ROS1, and NTRK mutation status and ALK translocation status is available in source documentation at the site.
  7. ECOG performance status of 0 or 1.
  8. Measurable tumor lesions according to RECIST 1.1.
  9. Must be willing to release tumor biopsy specimen used for diagnosis of advanced or metastatic NSCLC (if available) for exploratory tumor molecular profiling. If tumor biopsy specimen is not available, subjects can still be enrolled.
  10. Must be willing to provide blood samples prior to the start of treatment on this study for exploratory tumor molecular profiling analysis.
  11. Must be willing to provide a tumor biopsy specimen 9 weeks after the start of treatment for exploratory analyses, if considered safe by the Investigator.
  12. Ability to attend required study visits and return for adequate follow-up, as required by this protocol
  13. Agreement to practice effective contraception for female subjects of child-bearing potential and non-sterile males. Female subjects of child-bearing potential must agree to use effective contraception for up to 1 year after completion of therapy, and non-sterile male subjects must agree to use a condom for up to 4 months after treatment. Effective contraception includes surgical sterilization (eg, vasectomy, tubal ligation), two forms of barrier methods (eg, condom, diaphragm) used with spermicide, intrauterine devices (IUDs), hormonal therapy, and abstinence.

Exclusion Criteria:

  1. Serious uncontrolled concomitant disease that would contraindicate the use of the investigational drug used in this study or that would put the subject at high risk for treatment-related complications.
  2. A history of prior malignancy with the following exceptions: cancer treated with curative therapy with no disease recurrence for >3 years, non-metastatic prostate cancer controlled with hormonal therapy, or under observation; non-metastatic thyroid cancer; basal or squamous cell carcinoma of the skin, superficial bladder cancer, or in situ cervical cancer that has undergone successful definitive resection.
  3. Systemic autoimmune disease (eg, lupus erythematosus, rheumatoid arthritis, Addison's disease, or autoimmune disease associated with lymphoma).
  4. History of organ transplant requiring immunosuppression; or history of pneumonitis or interstitial lung disease requiring treatment with systemic steroids; or a history of receiving systemic steroid therapy or any other immunosuppressive medication ≤ 3 days prior to study initiation. Daily steroid replacement therapy (eg, prednisone or hydrocortisone) and corticosteroid use to manage AEs are permitted.
  5. Prior systemic chemotherapy, major surgery, or thoracic radiation within 3 weeks of study initiation.
  6. Requirement for other forms of anticancer treatment while on trial, including maintenance therapy, other radiation therapy, and/or surgery. Palliative radiation is permitted.
  7. Known CNS metastases or carcinomatous meningitis. Subjects with previously treated, stable CNS metastases (no evidence of progression for ≥ 4 weeks, and resolution of neurologic symptoms to baseline state) are permitted in this study.
  8. History of receiving a live vaccine 30 days prior to study treatment.
  9. History of human immunodeficiency virus (HIV), or known active hepatitis B or C infection.
  10. An active infection requiring systemic IV therapy.
  11. History of or active inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis).
  12. Inadequate organ function, evidenced by the following laboratory results:

    1. Absolute neutrophil count < 1,500 cells/mm3.
    2. Platelet count < 100,000 cells/mm3.
    3. Total bilirubin greater the upper limit of normal (ULN; unless the subject has documented Gilbert's syndrome).
    4. Aspartate aminotransferase (AST [SGOT]) or alanine aminotransferase (ALT [SGPT]) > 1.5 × ULN.
    5. Alkaline phosphatase (ALP) levels > 2.5 × ULN.
    6. Serum creatinine > 2.0 mg/dL or 177 μmol/L or creatinine clearance < 40 mL/min (using the Cockcroft-Gault formula)
  13. Uncontrolled hypertension (systolic > 160 mm Hg and/or diastolic > 110 mm Hg) or clinically significant (ie, active) cardiovascular disease, cerebrovascular accident/stroke, or myocardial infarction within 6 months prior to first study medication; unstable angina; congestive heart failure of New York Heart Association grade 2 or higher; or serious cardiac arrhythmia requiring medication. Subjects with uncontrolled hypertension should be medically managed on a stable regimen to control hypertension prior to study entry.
  14. Dyspnea at rest due to complications of advanced malignancy or other disease requiring continuous oxygen therapy.
  15. Known hypersensitivity to any component of the study medication(s).
  16. Subjects taking any medication(s) (herbal or prescribed) known to have an adverse drug reaction with any of the study medications.
  17. Participation in an investigational drug study or history of receiving any investigational treatment within 30 days prior to screening for this study, except for testosterone-lowering therapy in men with prostate cancer.
  18. Assessed by the Investigator to be unable or unwilling to comply with the requirements of the protocol.
  19. Concurrent participation in any interventional clinical trial.
  20. Pregnant and nursing women.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03520686


Contacts
Layout table for location contacts
Contact: Brooke Greenley, BS 919-810-0367 Brooke.Greenley@ImmunityBio.com
Contact: Jayson Garmizo, MEng 310-912-2230 Jayson.Garmizo@ImmunityBio.com

Locations
Show Show 25 study locations
Sponsors and Collaborators
ImmunityBio, Inc.
Investigators
Layout table for investigator information
Study Director: Chad Garner, PhD VP, Clinical Operations & Development
Layout table for additonal information
Responsible Party: ImmunityBio, Inc.
ClinicalTrials.gov Identifier: NCT03520686    
Other Study ID Numbers: QUILT-2.023
First Posted: May 11, 2018    Key Record Dates
Last Update Posted: March 3, 2021
Last Verified: February 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by ImmunityBio, Inc.:
Pembrolizumab
N-803
Non-Small Cell Lung Cancer
Immunotherapy
Carboplatin
Cisplatin
Nab-paclitaxel
Paclitaxel
Pemetrexed
Chemotherapy
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma, Non-Small-Cell Lung
Lung Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Paclitaxel
Albumin-Bound Paclitaxel
Cisplatin
Carboplatin
Pembrolizumab
Pemetrexed
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents, Immunological
Enzyme Inhibitors
Folic Acid Antagonists
Nucleic Acid Synthesis Inhibitors